Global News

FDA grants Soligenix Fast Track for OrbeShield for gastrointestinal acute radiation syndrome

Thursday, January 31, 2013 02:00 PM

Soligenix, a development-stage biopharmaceutical company, announced today that its OrbeShield (oral beclomethasone 17, 21-dipropionate or oral BDP) development program for the treatment of gastrointestinal acute radiation syndrome (GI ARS) has received Fast Track designation from the FDA.

More... »


Synteract appoints Kelson as CFO, Doren as vice president of biometrics

Wednesday, January 30, 2013 03:18 PM

Synteract, a full service CRO based in Carlsbad, Calif., has hired new executives to support customers on a global scale. Keith Kelson will serve as chief financial officer and member of its executive council, and Phil Doren has been appointed vice president of biometrics.

More... »


Curie-Cancer, GenoSplice ink bioinformatics partnership for cancer genomics

Wednesday, January 30, 2013 12:32 PM

Curie-Cancer, the body responsible for developing comprehensive cancer center Institut Curie’s industry partnership activities, and GenoSplice Technology, a developer of bioinformatics solutions for analysis of genomic data, have formed a partnership to combine their expertise.

More... »

Orexo, AZ enter research agreement for respiratory disease program

Wednesday, January 30, 2013 12:04 PM

Orexo, emerging specialty pharmaceutical company based in Sweden, has entered into an agreement with AstraZeneca regarding OX-CLI, a preclinical program for a potential novel treatment of respiratory diseases.

More... »

JLL Partners to acquire BioClinica and CoreLab Partners

Wednesday, January 30, 2013 11:36 AM

BioClinica, a global provider of clinical trial management solutions, has entered into a definitive agreement to be acquired by a holding company controlled by JLL Partners, a private equity firm.

More... »

PharmaNet/i3 renamed inVentiv Health Clinical

Wednesday, January 30, 2013 11:07 AM

inVentiv Health,  a global provider of clinical, commercial and consulting services, announced that its existing CRO, PharmaNet/i3, will be renamed inVentiv Health Clinical. This renaming reflects the closer alignment between the clinical segment and inVentiv's commercial and consulting services.

More... »

Afraxis grants exclusive global license to Genentech

Wednesday, January 30, 2013 09:42 AM

Afraxis, a San Diego-based biotechnology company fully funded by Avalon Ventures, has entered into a global licensing agreement with Genentech, a member of the Roche Group, to develop compounds for an undisclosed novel target.

More... »

Helsinn grants Especificos Stendhal rights to anamorelin for cachexia-anorexia in NSCLC

Wednesday, January 30, 2013 09:13 AM

Helsinn Group, a privately owned pharmaceutical group based in Switzerland, has granted Especificos Stendhal, a Latin American specialty company, exclusive commercialization rights for Mexico, Venezuela, Colombia, Perú, Ecuador and most of Central American countries, to this novel ghrelin receptor agonist.

More... »

Celsion, Zhejiang Hisun enter into tech development agreement for ThermoDox

Monday, January 28, 2013 10:24 AM

Celsion, an oncology drug development company, and Zhejiang Hisun Pharmaceutical, a Chinese pharmaceutical company, have entered into a technology development agreement for ThermoDox for the Greater China territory. 

More... »

DelMar Inc. acquires shares of DelMar Ltd.

Friday, January 25, 2013 01:43 PM

DelMar Pharmaceuticals, Inc., a Canadian pharmaceutical company that develops drug candidates targeting orphan cancer indications, has completed the acquisition of all of the outstanding shares of DelMar Pharmaceuticals Ltd., a clinical and commercial stage drug development company with a focus on the treatment of cancer. 

More... »

`

CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs